|Day Low/High||123.00 / 125.09|
|52 Wk Low/High||35.83 / 137.88|
Analysts are predicting that the legal pot market could reach $6.7 billion in sales this year.
Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.
GW Pharma could be the answer to an opiate addiction that isn't understood.
Cramer continues to back Apple and says Align Technology is a stock to buy now.
Investors hate uncertainty, Cramer says, but uncertainty creates bargains.
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
GW Pharmaceuticals (GWPH) said on Monday its seizure drug epidiolex had positive results in a late-stage clinical trial.
Cramer is sticking with International Paper and likes Advanced Micro Devices.
This is not the time to sell in a panic, Cramer says.
The marijuana market is heating up as marijuana usage for medical and recreational purposes gains legitimacy.
GW Pharmaceuticals (GWPH) reportedly hired Morgan Stanley after it was approached by several companies about a possible takeover.
Cramer says sell Stryker and buy Zimmer Biomet, and take Randgold over Barrick Gold.
The economy needs consumers to buy, buy, buy but so far consumers have been all over the map, Cramer says.
Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.
Investors should stick with buying stocks in the utilities and consumer staples sectors, which rose higher in the aftermath of the Brexit vote and avoided the massive volatility.
Shares of GW Pharmaceuticals are on the rise after the company announced this morning positive Phase 3 results for its Epidiolex for the treatment of Lennox-Gastaut syndrome, or LGS.
Trade-Ideas LLC identified GW Pharmaceuticals (GWPH) as a pre-market mover with heavy volume candidate
GW Pharmaceuticals announced positive results Monday from a second, pivotal clinical trial involving children with a severe form of epilepsy treated with its experimental marijuana-based drug.
Folks are anxious, dying to be bullish yet also curbing their enthusiasm.